A Study of MK-7145 in Participants With Stable Heart Failure (MK-7145-011)

Inclusion Criteria:

• If female, must be of non-child bearing potential
• Stable (at least 3 months with no change in medications including either torsemide 10-40 mg once daily [QD], bumetadine 2 or 4 mg QD, or furosemide 20 to 80 mg QD) Class II heart failure as specified by the New York Heart Association (NYHA) functional classification for heart failure
• Body Mass Index (BMI) ≥17.5 and ≤35kg/m^2
• No present history of clinically significant uncontrolled arrhythmias or abnormality on electrocardiogram (ECG)
• No present history of decompensated or uncontrolled cardiac disease including but not limited to hemodynamically relevant significant heart valve disease or evidence of secondary cardiac damage
• Not categorized as class III or IV according to the NYHA
• Ejection Fraction >25% demonstrated by echocardiogram or other imaging modality within 6 months
• Nonsmoker and/or has not used nicotine or nicotine-containing products for at least 6 months

Exclusion Criteria:

• Mentally or legally institutionalized and/or incapacitated, has significant emotional problems or has a history of a clinically significant psychiatric disorder over the last 5 years. This includes any mood disorder requiring concomitant use of lithium
• Diagnosed with acute coronary syndrome or acute cardiovascular (CV) event within previous 6 months
• Unstable angina pectoris
• Diabetes requiring high dose peroxisome proliferator-activated receptor (PPAR) antagonist (e.g. >30 mg of pioglitazone) or unstable insulin use
• Infectious disease requiring concomitant use of aminoglycosides
• Low plasma potassium (hypokalemia)
• Recent (within 6 months) history of stroke, uncontrolled seizures, or uncontrolled major neurological disorder
• Urinary retention
• Active nephrocalcinosis, nephrolithiasis, or hypercalciuria
• Functional disability that can interfere with rising from a semi-recumbent position to the standing position
• History of malignant neoplastic disease
• Unable to refrain from the use of medication, including prescription and non-prescription drugs such as high-dose aspirin (≥325 mg/day), human immunodeficiency virus (HIV) protease inhibitors (ritonavir, indinavir, nelfinavir), macrolide antibiotics (erythromycin, telithromycin, clarithromycin), chloramphenicol, azole antifungals (fluconazole, ketoconazole, itraconazole, nefazodone, aprepitant, verapamil, diltiazem, etc.), anticonvulsants and mood stabilizers (e.g., phenytoin, carbamazepine, oxcarbazepine), barbiturates (phenobarbital), HIV non-nucleoside reverse transcriptase inhibitors (efavirenz, nevirapine, etravirine), rifampicin, modafinil, St Johns wort, cyproterone (antiandrogen, progestin), etc. beginning approximately 2 weeks (or 5 half-lives), prior to administration of the initial dose of study drug, throughout the study (including washout intervals between treatment periods) until the poststudy visit
• Current use any aluminum- or magnesium-containing antacids
• Consumes excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer [284 mL/10 ounces], wine [125 mL/4 ounces], or distilled spirits [25 mL/1 ounce]) per day
• Consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other caffeinated beverages per day
• Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) or participated in another investigational study within 4 weeks
• History of significant multiple and/or severe allergies (including latex allergy), or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food
• Regular user (including recreational use) of any illicit drugs or has a history of drug (including alcohol) abuse within approximately 6 months